Stockscreener 앱 받기
39.72
2.98%
1.15
시간 외 거래:
39.47
-0.25
-0.63%
Rapport Therapeutics Inc 주식(RAPP)의 최신 뉴스
How Broad Russell Index Additions At Rapport Therapeutics (RAPP) Have Changed Its Investment Story - simplywall.st
RAPPRapport Therapeutics Inc Short Interest - Finviz
Rapport Therapeutics Hits New 52-Week High of $43.65 - MarketsMojo
Insider Sell: Cheryl Gault Sells 10,000 Shares of Rapport Therap - GuruFocus
Understanding the Setup: (RAPP) and Scalable Risk - Stock Traders Daily
Rapport Therapeutics (RAPP) COO sells 10,000 shares in pre-set 10b5-1 trades - Stock Titan
Rapport Therapeutics (RAPP) CEO sells 8,220 shares under Rule 10b5-1 plans - Stock Titan
[144] Rapport Therapeutics, Inc. SEC Filing - Stock Titan
Rapport Therapeutics stock hits all-time high at 42.36 USD By Investing.com - Investing.com Nigeria
Rapport Therapeutics, Inc.(NasdaqGM: RAPP) added to Russell 2500 Growth Benchmark - marketscreener.com
Rapport Therapeutics, Inc.(NasdaqGM:RAPP) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Rapport Therapeutics, Inc.(NasdaqGM: RAPP) added to Russell 2000 Growth Benchmark - marketscreener.com
Rapport Therapeutics, Inc.(NasdaqGM: RAPP) added to Russell 3000E Growth Benchmark - marketscreener.com
Rapport Therapeutics, Inc.(NasdaqGM:RAPP) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Rapport Therapeutics, Inc. Actuals & Estimates (NASDAQ:RAPP) - TradingView
RAPP Forecast — Price Target — Prediction for 2027 - TradingView
RAPP Initiated Coverage by Leerink Partners -- Rating set to Out - GuruFocus
Leerink Partners Initiates Rapport Therapeutics at Outperform With $52 Price Target - marketscreener.com
Leerink initiates Rapport Therapeutics stock with outperform rating By Investing.com - Investing.com Nigeria
Rapport Therapeutics Inc (RAPP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rapport Therapeutics Inc (RAPP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
The Technical Signals Behind (RAPP) That Institutions Follow - Stock Traders Daily
Rapport Therapeutics Inc (RAPP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Rapport Therapeutics Inc (RAPP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rapport Therapeutics Inc (RAPP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Rapport Therapeutics Inc (RAPP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Rapport Therapeutics Inc (RAPP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rapport Therapeutics Inc (RAPP) Institutional Confidence - TradingKey
Is Rapport Therapeutics (RAPP) a Good Stock to Buy? - HarianBasis.co
Is Rapport Therapeutics, Inc. (RAPP) A Good Stock To Buy Now? - Insider Monkey
Rapport ‘fully prepared’ to launch seizure drug solo, CEO says - BioPharma Dive
Rapport Therapeutics (RAPP) director receives 15,200 stock options grant - Stock Titan
[Form 4] Rapport Therapeutics, Inc. Insider Trading Activity - Stock Titan
Rapport Therapeutics (RAPP) director receives 15,200-share stock option grant - Stock Titan
Rapport Therapeutics (RAPP) director granted 15,200 stock options at $35.21 - Stock Titan
Rapport Therapeutics Holds 2026 Annual Shareholder Meeting - TipRanks
Rapport Therapeutics (RAPP) holders elect Class II board, ratify PwC - Stock Titan
Goldman Sachs Group Inc. Buys 579,903 Shares of Rapport Therapeutics, Inc. $RAPP - MarketBeat
Precision Trading with Rapport Therapeutics Inc. (RAPP) Risk Zones - Stock Traders Daily
Rapport Therapeutics (RAPP) Edges Higher Amid Tight Trading RangePut Flow Alert - newsline.com
Rapport Therapeutics (RAPP) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Is Rapport Therapeutics (RAPP) Using RAP-219 To Redefine Its Broader Neuroscience Investment Narrative? - Yahoo Finance
Wall Street Firms Raise Rapport Therapeutics Price Targets - sekbernews.id
BTIG and Truist Raise Price Targets for Rapport Therapeutics - HarianBasis.co
BTIG Raises its Price Target on Rapport Therapeutics (RAPP) - Insider Monkey
RAPP Advances RAP-219 Into Phase 3, Raising the Stakes in Focal Epilepsy - TipRanks
5 Stocks That Have the Potential to Rise 1000% - Insider Monkey
Number of shareholders of Rapport Therapeutics, Inc. – NASDAQ:RAPP - TradingView
BTIG Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $65 - Moomoo
Citizens reiterates Rapport Therapeutics stock rating on competitor trial data - Investing.com
Citizens reiterates Rapport Therapeutics stock rating on competitor trial data By Investing.com - Investing.com Canada
Rapport Therapeutics (RAPP) Q1 2026 Earnings: Narrower Loss Beats Estimates; Stock Holds Steady - newsline.com
Technical Reactions to RAPP Trends in Macro Strategies - Stock Traders Daily
Rapport Therapeutics (RAPP) Slides Slightly as Stock Tests Key Support ZoneADD Alert - dars.gov.et
Rapport Therapeutics (RAPP) Holds Steady as Minor Decline Tests Key Support LevelsKeltner Channel - newsline.com
Third Rock sells 836,136 RAPP shares across April–May 2026 (RAPP) - Stock Titan
Rapport Therapeutics Inc. (RAPP) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Stock GainProduct Revenue Analysis - Newser
1.17%
2.48%
자본화:
|
볼륨(24시간):